• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.

作者信息

Walker John B, Hughes Bernadette, James Ian, Haddock Peter, Kluft Cornelis, Bajzar Laszlo

机构信息

Henderson Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada.

出版信息

J Biol Chem. 2003 Mar 14;278(11):8913-21. doi: 10.1074/jbc.m205006200.

DOI:10.1074/jbc.m205006200
PMID:12643276
Abstract

Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethylmercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The inhibitor-induced effects were both tissue-type plasminogen activator (tPA) and TAFIa concentration-dependent. Inhibitor-dependent prolongation was favored at lower tPA concentrations. The magnitude of the prolongation increased with TAFIa concentration, and the maximal prolongation observed at each TAFIa concentration increased saturably with respect to TAFIa. A theoretical maximal prolongation of 20-fold was derived from a plot of the maximum prolongation versus TAFIa. This represents, for the first time, a measurement of the maximal antifibrinolytic potential of TAFIa in vitro. Because TAFIa spontaneously decays, the stabilization of TAFIa was investigated as a mechanism explaining the inhibitor-dependent prolongation of lysis. Both inhibitors stabilized TAFIa in a concentration-dependent, non-saturable manner. Although their KI values differed by three orders of magnitude, TAFIa was identically stabilized when the fraction of inhibitor-bound TAFIa was the same. The data fit a model whereby only free TAFIa decays. Therefore, the variable effects of competitive inhibitors of TAFIa on fibrinolysis can be rationalized in terms of free TAFIa and lysis time relative to the half-life of TAFIa.

摘要

相似文献

1
Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.
J Biol Chem. 2003 Mar 14;278(11):8913-21. doi: 10.1074/jbc.m205006200.
2
Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.凝血酶可激活的纤维蛋白溶解抑制剂酶原在纤维蛋白溶解的减弱过程中不起重要作用。
J Biol Chem. 2008 Apr 4;283(14):8863-7. doi: 10.1074/jbc.M800127200. Epub 2008 Feb 5.
3
The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.纤溶系统的内在阈值受碱性羧肽酶调节,但活化的凝血酶激活的纤溶抑制物的抗纤溶作用强度因其不稳定性而被掩盖。
J Biol Chem. 2004 Jul 2;279(27):27896-904. doi: 10.1074/jbc.M401027200. Epub 2004 May 5.
4
Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.组织型纤溶酶原激活物抑制因子-1(TAFIa)的可逆性抑制剂既能促进也能抑制纤维蛋白溶解。
J Thromb Haemost. 2003 Jan;1(1):147-54. doi: 10.1046/j.1538-7836.2003.00028.x.
5
Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.凝血酶激活的纤溶抑制物(TAFI)以纤溶酶原激活物浓度依赖的方式影响纤维蛋白溶解。在内源性凝块溶解模型中对七种纤溶酶原激活物的研究。
Thromb Haemost. 2004 Mar;91(3):473-9. doi: 10.1160/TH03-06-0377.
6
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.稳定的活化凝血酶激活的纤溶抑制物变体的产生。
J Biol Chem. 2006 Jun 9;281(23):15878-83. doi: 10.1074/jbc.M509839200. Epub 2006 Apr 4.
7
Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.对血浆和重组凝血酶激活的纤维蛋白溶解抑制剂(TAFI)以及活化的TAFI在糖基化、凝血酶/血栓调节蛋白依赖性激活、热稳定性和酶学特性方面进行了比较。
J Biol Chem. 1998 Jan 23;273(4):2127-35. doi: 10.1074/jbc.273.4.2127.
8
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.用于评估凝血酶激活的纤溶抑制物激活形式抑制剂的组织型纤溶酶原激活剂转基因大鼠
Blood Coagul Fibrinolysis. 2018 Apr;29(3):314-321. doi: 10.1097/MBC.0000000000000723.
9
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.尿激酶型纤溶酶原激活剂(uPA)、单链尿激酶型纤溶酶原激活剂(scuPA)和组织型纤溶酶原激活剂(tPA)介导的血栓溶解受血浆纤溶酶原激活剂抑制因子-2(TAFI)调控。
J Thromb Haemost. 2003 Sep;1(9):2000-7. doi: 10.1046/j.1538-7836.2003.00383.x.
10
Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.稳定的凝血酶激活的纤溶抑制物(TAFIa)变体的比较评估:α-螺旋9和β-折叠11对TAFIa(不)稳定性的重要性
J Thromb Haemost. 2007 Oct;5(10):2105-12. doi: 10.1111/j.1538-7836.2007.02720.x. Epub 2007 Jul 31.

引用本文的文献

1
Dependence of clot structure and fibrinolysis on apixaban and clotting activator.凝块结构和纤维蛋白溶解对阿哌沙班和凝血激活剂的依赖性。
Res Pract Thromb Haemost. 2024 Oct 29;8(8):102614. doi: 10.1016/j.rpth.2024.102614. eCollection 2024 Nov.
2
Functional Food Based on Potato.基于马铃薯的功能性食品。
Foods. 2023 May 26;12(11):2145. doi: 10.3390/foods12112145.
3
VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.VhH 抗血栓调节蛋白克隆 1 抑制 TAFI 在流动状态下的人全血中的活化,并增强纤溶。
J Thromb Haemost. 2022 May;20(5):1213-1222. doi: 10.1111/jth.15674. Epub 2022 Mar 11.
4
Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.凝血酶激活的纤溶抑制物(TAFI):更新的叙述性综述。
Int J Mol Sci. 2021 Apr 1;22(7):3670. doi: 10.3390/ijms22073670.
5
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?羧肽酶 U(CPU、TAFi、CPB2)在血栓栓塞性疾病中的作用:在发现它的三十年后,我们对它了解多少?
Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883.
6
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.新型抗血栓药物:《抗栓治疗与血栓预防,第 9 版》:美国胸科医师学会循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e120S-e151S. doi: 10.1378/chest.11-2294.
7
Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?羧肽酶 U(TAFIa):纤维蛋白溶解治疗的新靶点?
J Thromb Haemost. 2009 Dec;7(12):1962-71. doi: 10.1111/j.1538-7836.2009.03596.x. Epub 2009 Aug 28.